CN115746000A - 用于调节布鲁顿酪氨酸激酶的化合物及方法 - Google Patents

用于调节布鲁顿酪氨酸激酶的化合物及方法 Download PDF

Info

Publication number
CN115746000A
CN115746000A CN202210903642.7A CN202210903642A CN115746000A CN 115746000 A CN115746000 A CN 115746000A CN 202210903642 A CN202210903642 A CN 202210903642A CN 115746000 A CN115746000 A CN 115746000A
Authority
CN
China
Prior art keywords
unsubstituted
substituted
independently
many embodiments
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210903642.7A
Other languages
English (en)
Chinese (zh)
Inventor
R·哈德逊
A-M·博索莱伊
R·A·米勒
E·弗纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiaxing Heji Pharmaceutical Co ltd
Original Assignee
Jiaxing Heji Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiaxing Heji Pharmaceutical Co ltd filed Critical Jiaxing Heji Pharmaceutical Co ltd
Publication of CN115746000A publication Critical patent/CN115746000A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN202210903642.7A 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法 Pending CN115746000A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US62/307,399 2016-03-11
US201662342004P 2016-05-26 2016-05-26
US62/342,004 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase
CN201780028799.7A CN109071455B (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780028799.7A Division CN109071455B (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法

Publications (1)

Publication Number Publication Date
CN115746000A true CN115746000A (zh) 2023-03-07

Family

ID=59789888

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210903642.7A Pending CN115746000A (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法
CN201780028799.7A Active CN109071455B (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780028799.7A Active CN109071455B (zh) 2016-03-11 2017-03-10 用于调节布鲁顿酪氨酸激酶的化合物及方法

Country Status (12)

Country Link
US (2) US10870652B2 (cg-RX-API-DMAC7.html)
EP (1) EP3426637B1 (cg-RX-API-DMAC7.html)
JP (1) JP6972002B2 (cg-RX-API-DMAC7.html)
KR (1) KR102416971B1 (cg-RX-API-DMAC7.html)
CN (2) CN115746000A (cg-RX-API-DMAC7.html)
AU (1) AU2017230098B2 (cg-RX-API-DMAC7.html)
ES (1) ES2912465T3 (cg-RX-API-DMAC7.html)
IL (1) IL261583A (cg-RX-API-DMAC7.html)
MX (1) MX388026B (cg-RX-API-DMAC7.html)
PL (1) PL3426637T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017156495A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805951B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426637B1 (en) * 2016-03-11 2022-02-09 Angel Pharmaceutical Co., Ltd. Compounds and methods for modulating bruton's tyrosine kinase
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
US11554118B2 (en) * 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
CN118027041A (zh) 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
US11739090B2 (en) 2019-09-26 2023-08-29 Jumbo Drug Bank Co., Ltd. Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors
CN114437078A (zh) * 2020-11-03 2022-05-06 海思科医药集团股份有限公司 一种降解btk的氘代物及其在医药上的应用
US12655150B2 (en) 2021-03-26 2026-06-16 Cedilla Therapeutics, Inc. TEAD inhibitors and uses thereof
WO2022253250A1 (zh) * 2021-06-01 2022-12-08 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
TW202321191A (zh) * 2021-07-29 2023-06-01 美商賽迪拉治療股份有限公司 Tead抑制劑及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057877A1 (en) * 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
WO2007070398A1 (en) * 2005-12-13 2007-06-21 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
WO2007095223A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
WO2011099764A2 (en) * 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Novel pyrimidine derivative for inhibiting the growth of cancer cells
WO2013010136A2 (en) * 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20160000792A1 (en) * 2008-07-16 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) * 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
US8633318B2 (en) 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2809673B1 (en) 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
US9572811B2 (en) 2012-08-03 2017-02-21 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA3103411A1 (en) 2013-10-25 2015-04-30 Pharmacyclics Llc Use of ibrutinib for treating and preventing chronic graft versus host disease
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
US10358446B2 (en) * 2015-10-14 2019-07-23 Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
AU2017208998B2 (en) * 2016-01-21 2021-07-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Bruton's tyrosine kinase inhibitors
EP3426637B1 (en) * 2016-03-11 2022-02-09 Angel Pharmaceutical Co., Ltd. Compounds and methods for modulating bruton's tyrosine kinase

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057877A1 (en) * 1999-03-26 2000-10-05 Euro-Celtique S.A. Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
WO2007070398A1 (en) * 2005-12-13 2007-06-21 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
WO2007095223A2 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
US20160000792A1 (en) * 2008-07-16 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2011099764A2 (en) * 2010-02-09 2011-08-18 Hanmi Holdings Co., Ltd. Novel pyrimidine derivative for inhibiting the growth of cancer cells
WO2013010136A2 (en) * 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
KR20180133415A (ko) 2018-12-14
ES2912465T3 (es) 2022-05-26
MX388026B (es) 2025-03-19
EP3426637A4 (en) 2019-09-18
JP6972002B2 (ja) 2021-11-24
IL261583A (en) 2018-10-31
MX2018010971A (es) 2019-03-28
JP2019507793A (ja) 2019-03-22
CN109071455A (zh) 2018-12-21
WO2017156495A1 (en) 2017-09-14
WO2017156495A8 (en) 2018-09-27
KR102416971B1 (ko) 2022-07-04
US10870652B2 (en) 2020-12-22
US11306099B1 (en) 2022-04-19
EP3426637B1 (en) 2022-02-09
CN109071455B (zh) 2022-08-02
US20190106423A1 (en) 2019-04-11
AU2017230098A1 (en) 2018-09-20
CA3017567A1 (en) 2017-09-14
EP3426637A1 (en) 2019-01-16
PL3426637T3 (pl) 2022-05-30
ZA201805951B (en) 2020-12-23
NZ745927A (en) 2024-05-31
AU2017230098B2 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
CN109071455A (zh) 用于调节布鲁顿酪氨酸激酶的化合物及方法
JP7644517B2 (ja) Kras突然変異型タンパク質阻害剤
CN113286794B (zh) Kras突变蛋白抑制剂
CN108699035B (zh) 新化合物
WO2024017392A1 (zh) 嘧啶环类化合物、其中间体、其药物组合物及其应用
CN109890820B (zh) 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物
CN108601769B (zh) 吡唑化合物及其制备和使用方法
CN116490184B (zh) 用于抑制egfr突变癌症的化合物及其药物用途
CN112574255A (zh) 一类基于有机胂的cdk抑制剂及其制备方法和用途
CN108290872A (zh) 作为DUBs抑制剂的氰基吡咯烷衍生物
KR102965724B1 (ko) Cdk 억제제로서 치환된 피라졸로[1,5-a]피리미딘-7-아민 화합물 및 이들의 치료적 용도
JP2022533147A (ja) 芳香族アミン類のar及びbetを標的とするタンパク質分解キメラ化合物及び使用
TW201625629A (zh) 新穎吡咯并嘧啶化合物或其鹽,及含有其之醫藥組成物,特別是基於nae抑制作用的腫瘤等之預防劑及/或治療劑
CN121399103A (zh) 一类细胞程序性坏死抑制剂及其制备方法和用途
US20250136589A1 (en) Heterobifunctional compounds as hpk1 degraders
WO2024008097A1 (zh) 靶向降解cdk蛋白的化合物及其应用
WO2021061053A1 (en) Therapeutic compounds and methods of use thereof
WO2023116763A1 (zh) 一种哒嗪类化合物、其药物组合物及应用
US20260048131A1 (en) Bifunctional compounds and uses thereof
HK1262897B (en) Compounds and methods for modulating bruton's tyrosine kinase
HK1262897A1 (en) Compounds and methods for modulating bruton's tyrosine kinase
BR112019008656B1 (pt) Composto de aminopirazolopirimidina, composição farmacêutica que compreende o mesmo e uso do dito composto para a profilaxia ou o tratamento de uma doença mediada por receptor de tirosina quinase de fator neurotrófico
HK40002935B (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
HK40002935A (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
HK1256634B (en) Pyrazole compounds and methods of making and using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230307

WD01 Invention patent application deemed withdrawn after publication